Antiretroviral Drugs have become the mainstay for managing AIDS and works by retarding the progression of the disease and prolong the lifespan of HIV patients.
However a recent CDC report has revealed that 50% of the HIV positive gay and bisexual men did not take these medications.
HIV Positive patients study recent report from the Federal Centers for Disease Control and Prevention which was published in Morbidity and Mortality Weekly Report revealed that 50% of gay and bisexual men who have been tested positive for HIV are not using antiretroviral drugs. The treatment is especially scant among young men and blacks.
David Purcell, deputy director for behavioral and social science in the CDC’s HIV prevention division said that this is one more proof that one of the most prominent tools for protecting existing HIV patients and preventing the spread of the disease is being ignored.
The CDC report says that 77% of the gay and bisexual men who had been diagnosed as HIV positive in 2010 had obtained some initial care. This has been revealed by lab reports from 19 areas around the country. However researchers found that only b51% of all the infected gay and bisexual men got continuing care. The researchers also found that 49.5% were prescribed antiretroviral drugs which can suppress the multiplication of the virus and prevent it from destroying the immune system thus reducing the risks and prolonging the life span of the patients.
The drug treatment were even worse in infected men under 25(30%) and it reached 68% in men who are 55 years or more. The rate also varied according to race with Blacks receiving less treatment as compared to Hispanics and Whites.
Federal health officials started advocating treatment for all who are HIV positive, including those at the earliest stage of infection, in 2012, after the data were collected. However treatment gaps persist and are likely to continue. Prominent reasons for refusing treatment could be a state of denial that they are HIV positive, lack of insurance or perceived social stigma.